Format

Send to

Choose Destination
Therapie. 2018 Sep;73(4):341-348. doi: 10.1016/j.therap.2018.03.004. Epub 2018 Mar 30.

[Understanding the distrust towards the assessment of medicines. Beyond conflict of interests].

[Article in French]

Author information

1
CNRS, Centre de recherche politique de Sciences Po (CEVIPOF), 98, rue de l'université, 75007 Paris, France. Electronic address: virginie.tournay@sciencespo.fr.
2
Pôle de santé publique, centre régional de pharmacovigilance de Bordeaux, service de pharmacologie médicale, CHU de Bordeaux, 33000 Bordeaux, France.

Abstract

This article aims at analyzing mechanisms leading to a situation of mistrust about the scientific evaluation of the medicinal product, beyond issues related to links of interests. The assumption is that conflicts of interest are only one component of this mistrust. It doesn't explain all social controversies affecting this sector, in particular the credibility of drug evaluation systems. We explore here how, during the six stages of certification that characterize the trajectory of the drug and its evaluation - the functioning of scientific production and collective representations contribute to this mistrust. Without any analyses on the precise mechanisms of this mistrust, the loss of legitimacy of institutions and of scientific evaluation will increase. This goes hand in hand with a potential risk to public health.

KEYWORDS:

Confiance; Conflict of interest; Conflit d’intérêt; Drug; Evaluation; Médicament; Opinion publique; Public opinion; Trust; Évaluation

Supplemental Content

Loading ...
Support Center